HwangTJKesselheimASSarpatwariA. Value-based pricing and state reform of prescription drug costs. JAMA. 2017;318:609–610.
2.
HulshofJA. Sustainable health care systems: the role of therapeutic value and value based pricing. Value Health. 2014;17: A452.
3.
RafteryJ.Value based pricing: Can it work?BMJ. 2013;347:f5941.
4.
CalleaGArmeniPMarsilioMJommiCTarriconeR. The impact of HTA and procurement practices on the selection and prices of medical devices. Soc Sci Med. 2017;174:89–95.
5.
PanteliDArickxFCleemputI. Pharmaceutical regulation in 15 European countries review. Health Syst Transit. 2016;18:1–122.
6.
BachPB. Indication-specific pricing for cancer drugs. JAMA. 2014;312:1629–30.
7.
BachPBPearsonSD. Payer and policy maker steps to support value-based pricing for drugs. JAMA. 2015;314:2503–2504.
8.
HuninkMGWeinsteinMCWittenbergEPliskinPGlasziouMFDrummondJBW. Decision Making in Health and Medicine. Cambridge: Cambridge University Press; 2014.
9.
TrippoliS. Incremental cost-effectiveness ratio and net monetary benefit: current use in pharmacoeconomics and future perspectives. Eur J Intern Med. 2017;43: e36.
MorrisSPatelNVDobsonJ. International Carotid Stenting Study investigators. Cost-utility analysis of stenting versus endarterectomy in the International Carotid Stenting Study. Int J Stroke. 2016;11:446–453.
12.
RadcliffKLernerJYangCBernardTZiglerJE. Seven-year cost-effectiveness of ProDisc-C total disc replacement: results from investigational device exemption and post-approval studies. J Neurosurg Spine. 2016;24:760–768.
13.
DylstPVultoASimoensS. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe?Health Policy. 2011;101:146–152.
